阿里健康（00241）：FY26H1自营业务板块增长带动整体业绩高增速，药品运营能力提升

阿里健康 AliHealth (241 HK) FY26H1 自营业务板块增长带动整体业绩高增速，药品运营能力提升 FY26 H1, the Growth of the self-Operated Business Segment Drove High Overall Performance Growth, and Pharmaceutical Operational Capabilities Improved 研究报告 Research Report 2 Dec 2025 [Table_yemei 观点聚焦 1] Investment Focus [Table_Info] 维持优于大市 Maintain OUTPERFORM 评级 优于大市 OUTPERFORM 现价 HK$5.51 目标价 HK$5.69 HTI ESG 4.0-4.0-4.0 E-S-G: 0-5, (Please refer to the Appendix for ESG comments) 市值 HK$88.85bn / US$11.41bn 日交易额 (3 个月均值) US$91.66mn 发行股票数目 16,125mn 自由流通 ...